Lucan · Conditions

Obstructive jaundice

Australian guidance: eTG Gastrointestinal + GESA + Cancer Council Australia Optimal Care Pathway for Pancreatic Cancer (2nd edition)

1. Definition and epidemiology

Jaundice (icterus) is yellow discolouration of skin, sclerae, and mucous membranes from bilirubin accumulation in tissue, clinically detectable once serum bilirubin exceeds approximately 34 to 50 micromol/L (scleral icterus, given the elastin-rich sclera's high bilirubin affinity, is often visible before skin colour change is apparent). Jaundice is classified aetiologically by where bilirubin handling fails: pre-hepatic (excess production overwhelming a structurally normal liver, classically haemolysis), hepatic (impaired hepatocyte uptake, conjugation, or excretion, classically viral hepatitis or cirrhosis), and post-hepatic or obstructive (mechanical blockage of bile flow after it has already left the hepatocyte, classically gallstones or malignancy). This note is anchored on post-hepatic jaundice, with particular focus on painless obstructive jaundice from pancreatic head and periampullary malignancy, the presentation that most reliably separates a surgical from a medical cause of jaundice in clinical practice (Curtin MY3 SRS 12 Jaundice).

Pancreatic ductal adenocarcinoma (PDAC) is the most important malignant cause of obstructive jaundice and one of the most lethal solid organ cancers. In Australia, an estimated 4,825 new cases were diagnosed in 2025 (age-standardised incidence approximately 17 per 100,000 persons), and pancreatic cancer was the fourth most common cause of cancer death in 2023, projected to become the third most common by 2025 with an estimated 4,039 deaths, despite ranking outside the ten most commonly diagnosed cancers overall — a mismatch between incidence and mortality that reflects how late most cases present. Five-year survival has improved only modestly, from 3.2 percent for cases diagnosed 1987 to 1991 to approximately 11 percent for cases diagnosed 2012 to 2016. Approximately 60 to 70 percent of PDAC arises in the head of the pancreas, precisely the anatomical relationship that produces painless obstructive jaundice as an early feature, in contrast with body and tail tumours, which usually present later with pain, weight loss, or metastatic disease because they do not encroach on the bile duct.

2. Pathophysiology

2.1 Bilirubin metabolism end to end

Understanding obstructive jaundice requires tracing bilirubin from red cell breakdown to stool colour. Senescent erythrocytes are phagocytosed by macrophages of the reticuloendothelial system, principally in the spleen, liver Kupffer cells, and bone marrow (Robbins Ch 18). Haem is cleaved by haem oxygenase to biliverdin, releasing iron for recycling and carbon monoxide as a by-product; biliverdin reductase then reduces biliverdin to unconjugated (indirect) bilirubin. Unconjugated bilirubin is lipophilic and water-insoluble, so it circulates tightly bound to albumin, which prevents glomerular filtration and explains why unconjugated hyperbilirubinaemia never appears in urine.

At the hepatic sinusoid, unconjugated bilirubin dissociates from albumin and is taken up by hepatocytes, then conjugated in the smooth endoplasmic reticulum by UDP-glucuronosyltransferase 1A1 (UGT1A1), which attaches one or two glucuronic acid molecules to form conjugated (direct) bilirubin. Conjugation renders bilirubin water-soluble and permits its active transport across the canalicular membrane into bile via the MRP2 transporter. This conjugation step is the decisive branch point for the three-way classification: pre-hepatic and most hepatic causes of jaundice act before or during conjugation, so unconjugated bilirubin predominates; obstructive jaundice acts entirely after conjugation, so the bilirubin that accumulates is conjugated.

Bile is concentrated in the gallbladder and released into the duodenum with cholecystokinin-driven contraction. In the terminal ileum and colon, gut bacteria deconjugate and reduce bilirubin to urobilinogen, a colourless compound. Most urobilinogen is oxidised to stercobilin and excreted in stool, producing normal brown stool colour; a smaller fraction is reabsorbed into the portal circulation (the enterohepatic urobilinogen circuit), the majority of which is re-excreted in bile, with a small residual amount filtered by the kidney and excreted in urine.

2.2 Mapping metabolism to the three-way classification

Pre-hepatic (haemolytic) jaundice floods the system with unconjugated bilirubin faster than hepatic conjugating capacity, but hepatocyte uptake, conjugation, and excretion, and biliary flow into the gut, are all structurally normal. Because the excess pigment is unconjugated and albumin-bound, none of it is filtered by the kidney, so urine colour is normal and dipstick bilirubin is negative. Because bile flow into the gut is unimpeded (and the bilirubin load reaching the gut is if anything increased), stercobilin production is preserved or increased, so stools remain normal or darker, and urinary urobilinogen is typically increased. There is no cholestasis, so bile constituents do not accumulate in skin and pruritus does not occur. This is why pre-hepatic jaundice gives none of the three cardinal obstructive features: normal urine colour, normal or dark stool, and no itch.

Hepatic (hepatocellular) jaundice damages the hepatocyte itself, impairing uptake, conjugation, and canalicular excretion together, so the resulting hyperbilirubinaemia is typically mixed, and the biochemical picture is dominated by markedly elevated transaminases (ALT and AST) reflecting hepatocyte injury, with proportionally smaller elevation of ALP and GGT unless a significant secondary cholestatic component is present.

Post-hepatic (obstructive) jaundice is mechanical failure of an otherwise intact excretory system: hepatocyte uptake and conjugation proceed normally, but a block distal to the canaliculi (choledocholithiasis, a pancreatic head mass, a biliary stricture) prevents conjugated bile from reaching the duodenum. Already water-soluble conjugated bilirubin backs up into hepatic sinusoids and the systemic circulation and, being loosely protein-bound, is freely filtered by the glomerulus, producing bilirubinuria and the dark, tea- or cola-coloured urine that is one cardinal feature of obstruction. Because no bilirubin reaches the colon, no stercobilin is formed: stools become pale, putty-coloured, or acholic (the second cardinal feature), and urinary urobilinogen, unlike urinary bilirubin, is characteristically reduced or absent — a combination (urine bilirubin present, urobilinogen absent) that is the mirror image of the pattern seen in haemolysis. Failure of biliary excretion also allows bile constituents that would normally leave the body in bile to accumulate systemically and deposit in skin, producing pruritus (the third cardinal feature); the precise pruritogen is debated, with bile acids correlating poorly with itch severity in some series and lysophosphatidic acid generated by the enzyme autotaxin increasingly implicated, but the trigger is cholestasis itself, present in obstruction and absent in pure pre-hepatic disease.

2.3 Courvoisier's law

In a patient with painless jaundice, a palpably enlarged, non-tender gallbladder makes gallstones an unlikely cause and should prompt urgent evaluation for malignant obstruction of the distal bile duct, classically carcinoma of the pancreatic head. The rationale is structural: chronic gallstone disease produces recurrent cystic duct obstruction, inflammation, and fibrosis that leave the gallbladder wall thickened, scarred, and non-distensible even under back-pressure, whereas malignant obstruction typically develops gradually in a previously healthy, thin-walled, compliant gallbladder that readily distends. Two recognised exceptions run in opposite directions. Benign disease can occasionally produce a palpable gallbladder with jaundice when two pathologies coexist, for example a stone impacted in the cystic duct causing a mucocele alongside a separate stone impacted in the common bile duct. More important not to miss, malignant obstruction can occur without a palpable gallbladder: a hilar (Klatskin) cholangiocarcinoma arising proximal to the point where the cystic duct joins the common hepatic duct obstructs bile flow above the gallbladder's own drainage point, so the gallbladder is never exposed to the elevated pressure and does not distend, and a pancreatic cancer in a patient with a pre-existing fibrotic gallbladder from coexisting gallstones will likewise have a non-palpable gallbladder despite malignant obstruction.

2.4 Pancreatic ductal adenocarcinoma

More than 90 percent of PDAC carries an activating KRAS mutation, typically an early event in progression from normal ductal epithelium through increasingly dysplastic pancreatic intraepithelial neoplasia (PanIN 1 to 3) to invasive carcinoma, mirroring the stepwise adenoma-carcinoma model of colorectal cancer (Robbins Ch 19). Inactivation of the CDKN2A/p16 tumour suppressor is an intermediate event, and TP53 and SMAD4 (DPC4) inactivation are typically late events associated with more aggressive, metastatic disease. The tumour provokes an intense desmoplastic (fibrotic) stromal reaction that contributes to its hard, gritty texture, its relative hypovascularity and chemoresistance, and its tendency to encase rather than simply displace adjacent vessels. Perineural invasion is common and extends into the retroperitoneal coeliac plexus, explaining the severe boring epigastric pain radiating to the back that characterises locally advanced disease, particularly body and tail tumours. Anatomically, the intrapancreatic segment of the distal common bile duct runs through or immediately behind the head of the pancreas before joining the pancreatic duct at the ampulla of Vater; a tumour arising in the pancreatic head therefore compresses the bile duct directly, which is why painless obstructive jaundice is a comparatively early presenting feature of head-of-pancreas tumours but not of body or tail tumours.

3. Clinical presentation and diagnostic criteria

The Optimal Care Pathway for Pancreatic Cancer lists the presentations that should trigger urgent investigation: progressive painless jaundice with unexplained weight loss and abdominal discomfort; acute pancreatitis with no identifiable alcohol or gallstone cause; new-onset diabetes mellitus, particularly over age 50 without the usual risk factors for type 2 diabetes (pancreatic cancer can itself induce a paraneoplastic diabetogenic state that sometimes precedes diagnosis by a year or more); unexplained, unrelenting epigastric or back pain; and incidental pancreatic lesions found on imaging performed for another indication. The classic presentation of a head-of-pancreas tumour is painless, progressive jaundice with pale stools, dark urine, and pruritus, together with anorexia and unintentional weight loss; pain, when present, suggests more locally advanced or retroperitoneal disease. Migratory superficial thrombophlebitis (Trousseau syndrome), a paraneoplastic hypercoagulable state, and a palpable, non-tender gallbladder (Courvoisier sign) are recognised but comparatively late or inconsistent findings.

Established risk factors for PDAC include cigarette smoking (the single strongest modifiable risk factor, associated with an approximately two-fold increase in risk and a dose-dependent relationship), long-standing chronic pancreatitis (particularly hereditary pancreatitis from PRSS1 mutations), longstanding type 2 diabetes, obesity, and increasing age, together with hereditary cancer syndromes including germline BRCA1/BRCA2 and PALB2 mutations, Peutz-Jeghers syndrome (STK11), familial atypical multiple mole melanoma syndrome (CDKN2A), and Lynch syndrome. A family history of pancreatic cancer in a first-degree relative independently increases risk and should prompt consideration of genetic counselling.

Benign causes of obstructive jaundice must remain in the differential, particularly because chronic pancreatitis and malignancy can genuinely be difficult to distinguish on imaging alone. Choledocholithiasis, a gallstone that has migrated into the common bile duct, typically causes colicky right upper quadrant or epigastric pain with a fluctuating, intermittent jaundice pattern as the stone partially or transiently obstructs the duct, and carries a risk of superimposed ascending cholangitis if the trapped bile becomes infected. Chronic pancreatitis, most often from long-standing alcohol use, can produce a fibrotic stricture of the intrapancreatic bile duct as it traverses the scarred pancreatic head, causing obstructive jaundice without malignancy; mass-forming chronic or autoimmune pancreatitis can mimic a tumour closely enough on imaging that endoscopic ultrasound-guided tissue sampling, or occasionally resection, is required to exclude cancer with confidence. Primary sclerosing cholangitis (PSC) is a chronic, progressive, fibro-obliterative inflammatory disease of the intrahepatic and extrahepatic bile ducts, strongly associated with inflammatory bowel disease: 70 to 80 percent of PSC patients have coexisting IBD, most commonly ulcerative colitis, and perinuclear antineutrophil cytoplasmic antibody (p-ANCA) is positive in up to 80 percent of cases. PSC typically affects young to middle-aged men, presents with fatigue, pruritus, and a fluctuating cholestatic biochemical pattern, and shows a characteristic multifocal "beaded" pattern of strictures and dilations on magnetic resonance cholangiopancreatography. Primary biliary cholangitis (PBC), by contrast, is an autoimmune, small-duct destructive cholangiopathy that overwhelmingly affects middle-aged women, presents with fatigue and pruritus often preceding jaundice, and is defined serologically by a positive anti-mitochondrial antibody (AMA) in approximately 90 to 95 percent of cases; associated findings include xanthelasma from cholesterol retention and coexisting autoimmune disease such as Sjögren syndrome or autoimmune thyroid disease.

4. Investigations and AU-specific cutoffs

The first biochemical task in any jaundiced patient is to characterise the pattern of liver injury, and the pattern is defined by the ratio of enzyme elevations, not by which individual enzyme happens to sit above its own reference range. The R ratio is calculated as (ALT as a multiple of its upper limit of normal) divided by (ALP as a multiple of its upper limit of normal): R greater than 5 indicates a hepatocellular pattern, R less than 2 indicates a cholestatic pattern, and R between 2 and 5 indicates a mixed pattern. A mildly elevated ALT in isolation does not make a picture "hepatocellular" if ALP and GGT are proportionally far higher, and a modestly elevated ALP does not indicate cholestasis if transaminases are elevated to a much greater degree. Because ALP is also produced by bone, placenta, and intestine, an isolated ALP rise is non-specific; gamma-glutamyl transferase (GGT) is far more specific to the hepatobiliary tract and is the standard discriminator — a concordant rise in ALP and GGT confirms a hepatobiliary source, whereas a raised ALP with a normal GGT points to a bony source such as Paget disease, fracture healing, bone metastases, or physiological elevation in pregnancy or childhood growth. In obstructive jaundice, ALP and GGT rise disproportionately to transaminases because the pathology is at the canalicular and biliary excretory interface rather than primary hepatocyte injury, giving an R ratio well below 2.

Coagulation studies are essential: a prolonged prothrombin time and INR in obstructive jaundice reflect fat-soluble vitamin K malabsorption rather than primary hepatocyte synthetic failure (see Section 5), and factor VII, with the shortest half-life of the vitamin K-dependent factors, is typically the first to fall, making INR a sensitive early marker. Serum CA 19-9 is a carbohydrate antigen tumour marker used in the assessment of suspected PDAC; sensitivity is approximately 79 to 81 percent and specificity 82 to 90 percent in symptomatic patients, but its diagnostic value is limited by two important caveats. Around 5 to 10 percent of the population is Lewis antigen-negative and cannot synthesise CA 19-9 at all, so a normal result does not exclude cancer in these individuals, and CA 19-9 is frequently and substantially falsely elevated by benign cholestasis and obstructive jaundice of any cause, as well as by pancreatitis and other malignancies. For these reasons CA 19-9 is not recommended as a screening or standalone diagnostic test; its principal use is as a marker of treatment response and disease recurrence once a tissue diagnosis has been made and a baseline level established. PSC is supported by p-ANCA positivity and characteristic MRCP beading; PBC is confirmed by a positive anti-mitochondrial antibody.

Imaging follows a staged pathway. Transabdominal ultrasound is typically the first investigation, useful for confirming biliary dilatation and detecting gallstones, but it images the pancreas poorly. Pancreatic-protocol contrast-enhanced CT (a dual- or triple-phase study with thin slices through the pancreas, timed to arterial and portal venous phases) is the definitive first-line staging investigation once a pancreatic mass is suspected, because it defines the tumour's relationship to the superior mesenteric artery, coeliac axis, common hepatic artery, and the superior mesenteric-portal venous confluence, which determines resectability. Endoscopic ultrasound (EUS) with fine-needle aspiration or core biopsy provides both tissue diagnosis and high-resolution locoregional staging in a single procedure and is typically the next step once CT suggests a potentially resectable lesion. Magnetic resonance cholangiopancreatography further delineates biliary anatomy. Formal staging adds CT of the chest, abdomen, and pelvis with PET, and MRI of the pancreas or liver where indicated, and diagnostic laparoscopy with or without laparoscopic ultrasound is used immediately before planned resection in high-risk patients to exclude small-volume peritoneal or hepatic metastases not visible on cross-sectional imaging.

The Optimal Care Pathway sets explicit Australian timeframes: patients presenting with jaundice should be referred for tests within 48 hours, other suspicious symptoms should be reviewed within two weeks, and all patients with suspected pancreatic cancer should be seen by an appropriate specialist within one week of referral; diagnostic investigations should be completed within two weeks of referral, and the case should be discussed by a multidisciplinary team (hepatopancreaticobiliary surgeon, medical and radiation oncologist, gastroenterologist, radiologist, and pathologist) within one week of completing staging. At diagnosis only 10 to 20 percent of patients have clearly resectable disease and around 80 percent present with locally advanced or metastatic disease; unresectability is defined radiologically by tumour contact of more than 180 degrees of the circumference of the superior mesenteric artery, coeliac axis, or common hepatic artery, or by tumoural invasion, rather than simple abutment, of the superior mesenteric or portal vein.

5. Management

Definitive management of resectable pancreatic head cancer is pancreaticoduodenectomy (the Whipple procedure), which removes the head of the pancreas, the duodenum, the distal common bile duct, the gallbladder, and the gastric antrum (or, in the pylorus-preserving variant, retains the pylorus), with reconstruction typically comprising a pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy or duodenojejunostomy. It is feasible only in the minority of patients whose disease is resectable at diagnosis, and the Optimal Care Pathway recommends surgery proceed within four weeks of diagnosis where clinically appropriate. In high-volume hepatopancreaticobiliary centres, perioperative mortality has fallen below 5 percent (compared with historical rates exceeding 20 percent before surgical, anaesthetic, and critical care advances and centralisation of care), although morbidity remains substantial at 30 to 40 percent, most commonly delayed gastric emptying and postoperative pancreatic fistula. Even after macroscopically complete resection, outcomes remain sobering: median survival is approximately 15 to 20 months and five-year survival only 8 to 15 percent, reflecting the high rate of occult micrometastatic disease at the time of surgery. Adjuvant chemotherapy improves survival further and should begin within 12 weeks of surgery; regimens are discussed in Section 6. Borderline resectable disease may be treated with neoadjuvant chemotherapy in an attempt to downstage the tumour before surgical reassessment.

For the majority of patients with locally advanced or metastatic disease at diagnosis, management is palliative, and relief of biliary obstruction is a central goal because uncontrolled cholestasis causes pruritus, coagulopathy, malnutrition from fat malabsorption, and risk of ascending cholangitis. Endoscopic retrograde cholangiopancreatography with placement of a biliary stent across the obstruction is the recommended first-line palliative measure; self-expanding metal stents provide longer patency and are preferred when life expectancy allows, whereas plastic stents are cheaper and preferred when a short prognosis is anticipated or when resection remains a future possibility, because metal stents are harder to remove and can complicate subsequent surgery. Percutaneous transhepatic biliary drainage is used when the ampulla cannot be reached endoscopically, and surgical biliary bypass (hepaticojejunostomy, sometimes combined with gastrojejunostomy for anticipated duodenal obstruction) is now reserved for patients undergoing laparotomy for another reason or where endoscopic and percutaneous options have failed. Palliative systemic chemotherapy (Section 6) and coeliac plexus neurolysis for refractory pain are additional components of palliative management.

Management of the benign differentials is more straightforward. Choledocholithiasis is treated with ERCP, sphincterotomy, and stone extraction, followed by cholecystectomy to prevent recurrence. Chronic pancreatitis strictures causing jaundice may require endoscopic or surgical biliary drainage once malignancy has been confidently excluded. PBC is treated first-line with ursodeoxycholic acid (Section 6), which slows histological progression; PSC has no proven disease-modifying medical therapy, and management centres on surveillance for cholangiocarcinoma and colorectal cancer and, in end-stage disease, liver transplantation. Pruritus is managed first by relieving the underlying obstruction wherever feasible, which resolves itch faster than any pharmacological measure; first-line symptomatic pharmacotherapy is a bile acid sequestrant such as cholestyramine, which binds bile salts and other pruritogens in the gut lumen and interrupts their enterohepatic circulation, although its efficacy depends on some residual bile flow reaching the gut and it is less effective in complete obstruction. Second-line options for refractory pruritus include rifampicin and opioid antagonists such as naltrexone.

6. Pharmacology and AU PBS notes

Vitamin K deficiency coagulopathy in obstructive jaundice is corrected with parenteral (intravenous or subcutaneous) phytomenadione (vitamin K1) rather than the oral route, typically 10 mg once daily for up to three days, with INR rechecked to confirm response. This route is deliberate: because bile acids are required in the gut lumen for micellar solubilisation and absorption of fat-soluble vitamin K, obstructive jaundice impairs the same enteral absorption pathway that oral vitamin K would need to use, whereas parenteral administration bypasses the gut entirely. Because hepatocyte synthetic and gamma-carboxylation machinery is structurally intact in pure obstructive jaundice, once vitamin K is delivered the deficient factors (II, VII, IX, and X, plus proteins C and S) are resynthesised and INR typically normalises within 24 to 48 hours. This response is diagnostically useful: failure of INR to correct after parenteral vitamin K points instead to hepatocellular synthetic failure (cirrhosis, fulminant hepatitis), where hepatocytes cannot manufacture clotting factors regardless of vitamin K availability, and fresh frozen plasma is required for immediate correction before any invasive procedure.

Cholestyramine for pruritus is typically dosed at 4 g one to four times daily, ideally timed around meals and separated from other oral medications by several hours because it binds a wide range of co-administered drugs in the gut. Ursodeoxycholic acid, first-line therapy for PBC, is typically dosed at 13 to 15 mg/kg/day in divided doses and is PBS-listed for chronic cholestatic liver disease. In metastatic PDAC, PBS-subsidised systemic chemotherapy options include FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and folinic acid), generally reserved for patients with good performance status given its toxicity, and gemcitabine combined with nab-paclitaxel as an alternative for less fit patients; both regimens improve survival modestly over gemcitabine monotherapy in metastatic disease. Analgesia for locally advanced disease follows the standard WHO analgesic ladder with early consideration of coeliac plexus neurolysis for refractory visceral pain.

7. Complications and monitoring

Post-Whipple complications include delayed gastric emptying (the most common complication, managed with prokinetics and nasogastric decompression as needed), postoperative pancreatic fistula from leakage of the pancreaticojejunostomy (occurring in up to 40 percent of cases in some series and the complication most associated with subsequent haemorrhage and sepsis), postpancreatectomy haemorrhage, and, longer term, exocrine pancreatic insufficiency (steatorrhoea, fat-soluble vitamin deficiency, weight loss, requiring pancreatic enzyme replacement) and new-onset or worsened diabetes mellitus from loss of functioning islet tissue. Biliary stents carry their own complications: occlusion with recurrent jaundice and risk of ascending cholangitis (more common with plastic than metal stents, hence the preference for metal stents when longer patency is needed), stent migration, and duodenal perforation.

PSC requires long-term surveillance because of its markedly elevated cancer risk: lifetime cholangiocarcinoma risk is approximately 10 to 20 percent (annual risk around 1 to 2 percent), and a new dominant or rapidly progressive stricture in a known PSC patient should prompt biliary brushing or biopsy to exclude malignant transformation rather than being assumed to be a further benign inflammatory stricture. Because of the strong ulcerative colitis association, PSC patients also require colonoscopic surveillance for colorectal cancer, typically annually, over and above standard population screening. PSC itself progresses to biliary cirrhosis and portal hypertension in advanced disease, with liver transplantation the only intervention shown to alter survival. PBC similarly progresses to cirrhosis if untreated or unresponsive to ursodeoxycholic acid, and chronic cholestasis in both PBC and PSC causes malabsorption of fat-soluble vitamins A, D, E, and K, with vitamin D deficiency contributing to metabolic bone disease and osteoporosis that should be actively monitored with bone density assessment.

For PDAC overall, prognosis remains poor across all stages: median survival from diagnosis ranges from approximately 10 to 30 months depending on stage and resectability, and five-year survival across all Australian cases diagnosed 2012 to 2016 was approximately 11 percent, up from 3.2 percent for cases diagnosed 1987 to 1991. Cholangiocarcinoma and ampullary carcinoma are less common causes of obstructive jaundice that deserve brief separate mention. Cholangiocarcinoma is classified by location as intrahepatic, perihilar (Klatskin tumour, the most common subtype), or distal extrahepatic, and is strongly associated with PSC, hepatolithiasis, choledochal cysts, and, in returned travellers from Southeast Asia, chronic liver fluke infection (Clonorchis sinensis, Opisthorchis viverrini); management follows a similar paradigm of resection where feasible (partial hepatectomy for intrahepatic or perihilar disease, pancreaticoduodenectomy for distal disease) or palliative stenting and chemotherapy, with a generally poor prognosis. Ampullary carcinoma, arising from the ampulla of Vater itself, typically obstructs the bile duct at a much smaller tumour size than pancreatic head cancer and therefore tends to present earlier and is more often resectable at diagnosis, giving it a substantially better prognosis (five-year survival roughly 30 to 50 percent after resection); it can rarely produce a "silver stool" sign, combining pale, fatty (acholic) stool from biliary obstruction with occult gastrointestinal blood loss from the ulcerated ampullary surface.

Written for Australian practice and grounded in the guidance named above. Study material only — not medical advice. Always check against current guidelines.